Drugs News and Research

RSS

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa.

12 Aug 2014

Researchers create synthetic ion transporter that triggers apoptosis in cancer cells

Researchers from the University of Southampton are part of an international team that has helped to create a molecule that can cause cancer cells to self-destruct by carrying sodium and chloride ions into the cells.

12 Aug 2014

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable."

12 Aug 2014

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today.

12 Aug 2014

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries.

12 Aug 2014

Studies detect integrons that cause resistance to various antibiotics

In Mexico the sale of antibiotics for human consumption is controlled to prevent misuse, although in the veterinary sector failure in the implementation of the Official Mexican Standard NOM-064-ZOO-2000, "Guidelines for veterinarian products prescription", has prompted common bacteria such as Escherichia coli and Salmonella spp to become resistant to regular drugs such as streptomycin, trimethoprim, ampicillin, gentamicin, and tetracycline as a result of excess drug use.

12 Aug 2014

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Researchers from The University of Texas at Austin and five other institutions have created a molecule that can cause cancer cells to self-destruct by ferrying sodium and chloride ions into the cancer cells.

12 Aug 2014

Osteoporosis drugs may not protect women from breast cancer

Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).

12 Aug 2014

Discovery of new mechanism could lead to next generation of drugs to treat schizophrenia

Discovery of a new mechanism of drug action could lead to the next generation of drugs to treat schizophrenia.

12 Aug 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

Research sheds light on role of hepatic mTORC1 in whole body physiology

The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer.

12 Aug 2014

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

Opioid compliance checklist shows promise for chronic pain management

Researchers have developed a brief and simple checklist that clinicians can use to monitor opioid adherence among people with chronic pain.

11 Aug 2014

GW researcher awarded grant to develop a model system to study PN infection

According to a recent World Health Organization report of the leading causes of death worldwide, one-third of all deaths are due to infectious and parasitic diseases. There are currently no vaccines for parasitic nematode (PN), or worm infections in humans, and development of new drugs and vaccines will stall until researchers have a better understanding of PN biology.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.

11 Aug 2014

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.

11 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

Drugs News and Research

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Researchers create synthetic ion transporter that triggers apoptosis in cancer cells

Research shows new drug candidate can stop tumor growth in animal models

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries

Studies detect integrons that cause resistance to various antibiotics

Researchers create synthetic molecule that can cause cancer cells to self-destruct

Osteoporosis drugs may not protect women from breast cancer

Discovery of new mechanism could lead to next generation of drugs to treat schizophrenia

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Research sheds light on role of hepatic mTORC1 in whole body physiology

New approach to knocking out parasite's genes

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Novogen receives funding support to commence studies in muscular dystrophy

Opioid compliance checklist shows promise for chronic pain management

GW researcher awarded grant to develop a model system to study PN infection

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News